JPWO2023135237A5 - - Google Patents
Info
- Publication number
- JPWO2023135237A5 JPWO2023135237A5 JP2024541809A JP2024541809A JPWO2023135237A5 JP WO2023135237 A5 JPWO2023135237 A5 JP WO2023135237A5 JP 2024541809 A JP2024541809 A JP 2024541809A JP 2024541809 A JP2024541809 A JP 2024541809A JP WO2023135237 A5 JPWO2023135237 A5 JP WO2023135237A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutically acceptable
- ethan
- indol
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263299599P | 2022-01-14 | 2022-01-14 | |
| US63/299,599 | 2022-01-14 | ||
| US202263384704P | 2022-11-22 | 2022-11-22 | |
| US63/384,704 | 2022-11-22 | ||
| PCT/EP2023/050702 WO2023135237A1 (en) | 2022-01-14 | 2023-01-13 | Tryptamine compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025502208A JP2025502208A (ja) | 2025-01-24 |
| JPWO2023135237A5 true JPWO2023135237A5 (https=) | 2026-01-20 |
| JP2025502208A5 JP2025502208A5 (https=) | 2026-01-20 |
Family
ID=85018123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541809A Pending JP2025502208A (ja) | 2022-01-14 | 2023-01-13 | トリプタミン組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250051279A1 (https=) |
| EP (1) | EP4463440A1 (https=) |
| JP (1) | JP2025502208A (https=) |
| KR (1) | KR20240134951A (https=) |
| AU (1) | AU2023207801B2 (https=) |
| CA (1) | CA3259235A1 (https=) |
| IL (1) | IL313889A (https=) |
| MX (1) | MX2024008691A (https=) |
| WO (1) | WO2023135237A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| ID28302A (id) | 1999-01-14 | 2001-05-10 | Teijin Ltd | Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu |
| GB0114272D0 (en) | 2001-06-12 | 2001-08-01 | Optinose As | Nasal delivery device |
| NZ514442A (en) | 1999-03-03 | 2003-08-29 | Optinose As | Nasal delivery device |
| GB0121568D0 (en) | 2001-09-06 | 2001-10-24 | Optinose As | Nasal delivery device |
| GB0019715D0 (en) | 2000-08-10 | 2000-09-27 | Pa Consulting Services | Device for delivering physiologically active agent in powdered form |
| ZA200306564B (en) | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
| JP4795637B2 (ja) | 2001-09-28 | 2011-10-19 | カーブ テクノロジー，インコーポレイティド | 鼻ネブライザー |
| GB0207422D0 (en) | 2002-03-28 | 2002-05-08 | Optinose As | Nasal devices |
| GB0207817D0 (en) | 2002-04-04 | 2002-05-15 | Optinose As | Nasal devices |
| GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20240096817A (ko) * | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12042564B2 (en) * | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
| JP2023544724A (ja) * | 2020-10-02 | 2023-10-25 | サイビン アイアールエル リミテッド | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
-
2023
- 2023-01-13 US US18/720,922 patent/US20250051279A1/en active Pending
- 2023-01-13 WO PCT/EP2023/050702 patent/WO2023135237A1/en not_active Ceased
- 2023-01-13 AU AU2023207801A patent/AU2023207801B2/en active Active
- 2023-01-13 CA CA3259235A patent/CA3259235A1/en active Pending
- 2023-01-13 JP JP2024541809A patent/JP2025502208A/ja active Pending
- 2023-01-13 MX MX2024008691A patent/MX2024008691A/es unknown
- 2023-01-13 IL IL313889A patent/IL313889A/en unknown
- 2023-01-13 EP EP23700949.3A patent/EP4463440A1/en active Pending
- 2023-01-13 KR KR1020247026687A patent/KR20240134951A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1461306B1 (en) | Quaternary ammonium compounds and their use as antimuscarinic agents | |
| WO2022261383A1 (en) | Novel prodrugs and conjugates of dimethyltryptamine | |
| US9029421B2 (en) | Process for the synthesis of arformoterol | |
| WO2008141057A1 (en) | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea | |
| JP2009526814A (ja) | 鏡像異性的に純粋なキヌクリジニルオキシピリダジン、及びニコチン性アセチルコリン受容体リガンドとしてのその使用 | |
| JPS63258476A (ja) | ヘキサヒドロ−８−ヒドロキシ−２，６−メタノ−２ｈ−キノリジン−３（４ｈ）−オンのエステル類及び関連化合物類 | |
| JPWO2023078604A5 (https=) | ||
| CN104610195B (zh) | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 | |
| JPWO2023135237A5 (https=) | ||
| CA2396304A1 (en) | Substituted aminomethyl-phenyl-cyclohexane derivatives | |
| CN1452614A (zh) | 芳基哌嗪衍生物及其作为精神药物的用途 | |
| JPWO2023036473A5 (https=) | ||
| WO2012126386A1 (zh) | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 | |
| CN1258290A (zh) | 一种新的盐 | |
| CN101796027A (zh) | N-哌啶-4-基甲基-酰胺衍生物及其作为单胺神经递质再摄取抑制剂的用途 | |
| CN112759544B (zh) | 3-(二甲氨基甲基)哌啶-4-醇衍生物制备方法和药物用途 | |
| WO2008080290A1 (en) | Selective m4 receptor antagonist and its medical use | |
| JPWO2022038171A5 (https=) | ||
| JP6434591B2 (ja) | ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用 | |
| WO2014008639A1 (zh) | 制备茚达特罗的方法 | |
| CN109265374B (zh) | 一种氘代二甲羟胺苯甲酸酯类化合物及其制备方法和应用 | |
| EP1656375B1 (en) | Novel quinuclidine derivatives and their pharmaceutical use | |
| US6489342B2 (en) | Aryloxy piperidinyl indoles for treating depression | |
| JP2003514889A (ja) | Ｏ−デスメチルベンラファキシンのエーテル | |
| CN103360276B (zh) | 阿戈美拉汀的晶型、制备方法和用途、以及药物组合物 |